Table 1.
Rational combinations with histone deacetylase inhibitors: current Phase II/III clinical trials.
| HDACi | Cancer | Combination(s) |
|---|---|---|
| Vorinostat | Breast | Paclitaxel/trastuzumab/doxorubicin/cyclophosphamide; carboplatin/nab- paclitaxel; bevacizumab/paclitaxel; capecitabine; lapatinib |
| Glioma | Bevacizumab/temozolomide; temozoloamide/radiation therapy | |
| Glioblastoma multiforme | Carboplatin/isotretinoin; erlotinib/carboplatin | |
| NSCLC | Gefitinib; paclitaxel/radiation therapy | |
| Pancreatic | Fluorouracil/radiation therapy | |
| Ovarian | Carboplatin/paclitaxel | |
| Ovarian, fallopian tube or peritoneal | Carboplatin/gemcitabine | |
| Colorectal | Fluorouracil/leucovorin | |
| Renal | Carboplatin/isotretinoin | |
| Lymphoma | Pegylated liposomal doxorubicin | |
| T-cell lymphoma | Cyclophosphamide/vincristine/doxorubicin/prednisone | |
| DLBCL | Rituximab/cyclophosphamide/vincristine/prednisone | |
| Large B-cell lymphoma | Rituximab/cyclophosphamide/etoposide/prednisone | |
| HIV-associated DLBCL | Rituximab/cyclophosphamide/vincristine/doxorubicin/prednisone | |
| Panobinostat | Breast | Trastuzumab; letrozole |
| Prostate | Bicalutamide | |
| Renal cell | Everolimus | |
| Melanoma | Decitabine/temozolomide | |
| Multiple myeloma and lymphomas | Everolimus | |
| Valproic acid | Breast | 5-fluorouracil/epirubicin/cyclophosphamide |
| Gliomas | Temozolomide/radiation therapy; bevacizumab/radiation therapy | |
| Ovarian | Azacyitidine/carboplatin; hydralazine | |
| Cervical | Hydralazine | |
| Small-cell lung carcinoma | Adriamycin/cyclophosphamide/vindesine | |
| Mesothelioma | Doxorubicin | |
| Sarcomas | Bevacizumab/gemcitabine/docetaxel | |
| MDS | 5-azacytidine/ATRA | |
| MDS/AML | Decitabine; 5-azacytidine/ATRA | |
| AML | Decitabine/ATRA | |
| Belinostat | NSCLC | Carboplatin/paclitaxel/bevacizumab; erlotinib |
| Ovarian, fallopian tube or primary peritoneal cancer |
Carboplatin | |
| Cancer of unknown primary | Carboplatin/paclitaxel | |
| Soft tissue sarcoma | Doxorubicin | |
| Thymic malignancies | Cisplatin/doxorubicin/cyclophosphamide | |
| Entinostat | NSCLC | Azacitadine |
| Colorectal | Azacitadine | |
| PCI-24781 | Soft tissue sarcoma | Doxorubicin |
AML: Acute myeloid leukemia; ATRA: All-trans retinoic acid; DLBLC: Diffuse large B-cell lymphoma; HDACi: Histone deacetylase inhibitor; MDS: Myelodysplastic syndrome; NSCLC: Non-small-cell lung carcinoma.